Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer.
Autologous cancer-specific bulk CTLs are unlikely to be induced by in vitro CTL generation (ivtCTLG) using peripheral blood mononuclear cells (PBMCs) of cancer patients when autologous cancer cells are used as in vitro stimulators. However, autologous cancer-specific bulk CTLs are frequently activated when allogeneic cancer cells are used as in vitro stimulators, regardless of the type of cancer cell. We have developed a cancer-specific immunotherapy called modified CTL therapy, which involves adoptive immunotherapy of autologous cancer-specific bulk CTLs after active immunization of autologous or allogeneic cancer cells screened as in vitro stimulators according to their ability to induce autologous cancer-specific CTLs (ACS. CTLs). Cancer did not regress in patients in whom ACS.CTLs were not induced by ivtCTLG using the patients' PBMCs in therapy. Cancer regression, albeit temporary, occurred solely in patients under the immunological condition that ACS.CTLs were induced by ivtCTLG using PBMCs through the therapy. The induction of ACS.CTLs by ivtCTLG using patient PBMCs in therapy was related to patients' HLA class II antigens. HLA DR8 was seen more frequently in ACS.CTL-inducible patients than in ACS.CTL-uninducible patients (P=0.051). On the contrary, HLA DQ3 was seen more frequently in ACS.CTL-uninducible patients (P=0.055). On the other hand, the success in therapy, albeit temporary, was related mainly to patients' HLA class I antigens. HLA B61 was seen more frequently in patients whose therapy proved effective than in patients whose therapy proved ineffective (P=0.018). HLA Cw7 was seen more frequently in therapy-ineffective patients (P=0.040).
Araki
K
K
Department of Medicine, Atago General Hospital, Kochi-shi, Kochi 780-0056, Japan. araki@i-kochi.or.jp
Noguchi
Y
Y
Hirouchi
T
T
Yoshikawa
E
E
Kataoka
S
S
Silverni
L
L
Miyazawa
H
H
Kuzuhara
H
H
Suzuki
C
C
Shimada
Y
Y
Hamasato
S
S
Maeda
N
N
Shimamura
Y
Y
Ogawa
Y
Y
Ohtsuki
Y
Y
Fujimoto
S
S
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D002478:Cells, Cultured / Q000276:immunology / Q000637:transplantation; D005260:Female; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology*; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007114:Immunization; D016219:Immunotherapy, Adoptive; D007519:Isoantigens / Q000276:immunology*; D007564:Japan / Q000453:epidemiology; D007937:Leukapheresis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D006680:HLA Antigens; D007519:Isoantigens